Zoetis Inc. $ZTS Stock Position Cut by Sky Investment Group LLC

Sky Investment Group LLC decreased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 22.6% during the 4th quarter, Holdings Channel reports. The institutional investor owned 16,523 shares of the company’s stock after selling 4,835 shares during the period. Sky Investment Group LLC’s holdings in Zoetis were worth $2,079,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Halbert Hargrove Global Advisors LLC boosted its holdings in shares of Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares in the last quarter. Global Wealth Strategies & Associates acquired a new position in shares of Zoetis during the fourth quarter valued at approximately $25,000. KERR FINANCIAL PLANNING Corp bought a new stake in Zoetis during the third quarter worth approximately $31,000. Holos Integrated Wealth LLC acquired a new stake in Zoetis in the fourth quarter worth approximately $32,000. Finally, Board of the Pension Protection Fund acquired a new stake in Zoetis in the fourth quarter worth approximately $38,000. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several research analyst reports. Weiss Ratings cut Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday. UBS Group set a $136.00 price objective on Zoetis in a report on Thursday, January 29th. HSBC set a $140.00 target price on Zoetis in a research note on Wednesday, December 10th. BTIG Research reaffirmed a “buy” rating and set a $160.00 target price on shares of Zoetis in a report on Thursday, February 26th. Finally, William Blair reiterated an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Six equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Trading Down 2.7%

Zoetis stock opened at $113.48 on Friday. The firm has a market cap of $47.90 billion, a price-to-earnings ratio of 18.85, a price-to-earnings-growth ratio of 1.73 and a beta of 0.95. Zoetis Inc. has a 1 year low of $113.29 and a 1 year high of $172.23. The firm’s 50 day moving average price is $123.39 and its two-hundred day moving average price is $129.17. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.9%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio is currently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.